100 filings
PRE 14A
SHPH
Shuttle Pharmaceuticals Holdings Inc
10 Jun 24
Preliminary proxy
6:12am
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 May 24
Regulation FD Disclosure
4:15pm
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
14 May 24
Shuttle Pharma Provides First Quarter 2024 Corporate Update
9:00am
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Apr 24
Other Events
10:05am
8-K
mducwek0ki7s j68g0
23 Apr 24
Other Events
4:36pm
8-K
p5qs222g4yplbv8b p7
22 Mar 24
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
9:00am
424B3
8cyb0odu 7a
22 Mar 24
Prospectus supplement
6:07am
8-K
ks8 wx26s1
5 Mar 24
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
9:00am
8-K
5nn4l
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
wt3x3boewjq3e
5 Feb 24
Entry into a Material Definitive Agreement
4:25pm
8-K
la9nqe6or8r8 tex
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
vpnr0ub
19 Dec 23
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
515vkv0 t2iw5o
11 Dec 23
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
qb7 4b1sdgc920
30 Nov 23
Other Events
9:00am
8-K
4s19cbj cg
14 Nov 23
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
12:00am
8-K
h2k 9kd26ss4v2
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm